Children's Oncology Group 2023 blueprint for research: Cancer care delivery research.
National Cancer Institute's Community Oncology Research Program (NCORP)
cancer care delivery
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
05
07
2023
accepted:
06
07
2023
pmc-release:
01
09
2024
medline:
18
8
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
The National Cancer Institute (NCI) has a 40-year history of initiatives to encourage the participation of community oncology sites into clinical trials research and clinical care. In 2014, the NCI re-organized to form the NCI Community Oncology Research Program (NCORP) network across seven research bases, including the Children's Oncology Group (COG), and numerous community sites. The COG portfolio for Cancer Care Delivery Research (CCDR), mirroring the larger NCORP network, has included two studies addressing guideline congruence, as an important marker of quality cancer care, and another focusing on financial toxicity, addressing the pervasive problems of healthcare cost. CCDR is a cross-cutting field that frequently examines intersectional aspects of healthcare delivery. With that in mind, we explicitly define domains of CCDR to propel our research agenda into the next phase of the NCORP CCDR program while acknowledging the complex and dynamic fields of clinical care, policy level decisions, research findings, and needs of communities served by the NCORP network that will inform the subsequent research questions. To ensure programmatic success, we will engage a broad interdisciplinary group of investigators and clinicians with expertise and dedication to community oncology and the populations they serve.
Identifiants
pubmed: 37469004
doi: 10.1002/pbc.30579
pmc: PMC10686255
mid: NIHMS1940418
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30579Subventions
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189955
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
JAMA Intern Med. 2017 Dec 1;177(12):1855-1858
pubmed: 28973059
JCO Oncol Pract. 2020 Oct;16(10):e1060-e1066
pubmed: 32396490
Cancer. 2014 Jan 15;120(2):271-7
pubmed: 24122148
Psychooncology. 2020 Dec;29(12):2019-2027
pubmed: 32691478
J Natl Cancer Inst. 2020 Jun 1;112(6):557-561
pubmed: 31845965
J Pediatr Psychol. 2004 Apr-May;29(3):211-9
pubmed: 15131138
Pediatrics. 2016 Apr;137(4):
pubmed: 26962238
Eur J Cancer. 2007 Sep;43(13):1952-8
pubmed: 17624761
J Am Coll Radiol. 2017 Dec;14(12):1530-1537
pubmed: 29055605
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320
pubmed: 28209594
Cancer. 2019 Oct 15;125(20):3666-3677
pubmed: 31291014
Pediatrics. 2010 Jul;126(1):129-36
pubmed: 20547645
J Natl Cancer Inst. 2014 Sep 01;106(8):dju166
pubmed: 25178694
Pediatr Blood Cancer. 2013 Sep;60(9):1470-7
pubmed: 23512267
Pediatrics. 2004 Jun;113(6):1833-5
pubmed: 15173520
J Clin Oncol. 1994 Aug;12(8):1718-23
pubmed: 8040683
Oncologist. 2020 Dec;25(12):1032-1038
pubmed: 32820842
J Clin Oncol. 2015 Aug 10;33(23):2545-52
pubmed: 26150441
Cancer. 2016 May 15;122(10):1608-17
pubmed: 27028090
Cancer Epidemiol Biomarkers Prev. 2022 Jun 1;31(6):1243-1246
pubmed: 35642391
J Clin Oncol. 2012 Dec 10;30(35):4427-38
pubmed: 22987086
J Cancer Surviv. 2023 Apr;17(2):342-350
pubmed: 36870037
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28941160
J Clin Oncol. 2015 Aug 20;33(24):2705-11
pubmed: 26195715
J Pediatr Hematol Oncol. 2019 May;41(4):286-288
pubmed: 30124549
J Clin Oncol. 2010 Apr 1;28(10):1740-8
pubmed: 20194864
Pediatr Hematol Oncol. 2017 Apr;34(3):133-137
pubmed: 28922050
Psychooncology. 2013 Sep;22(9):2051-8
pubmed: 23401292
Crit Rev Oncol Hematol. 2020 Jan;145:102838
pubmed: 31786347
J Pediatr Oncol Nurs. 2019 Jan/Feb;36(1):6-16
pubmed: 30798687
J Oncol Pract. 2014 May;10(3):193-5
pubmed: 24839280
Cancer Med. 2019 Apr;8(4):1865-1874
pubmed: 30838816
J Clin Oncol. 2010 Feb 1;28(4):655-61
pubmed: 19841325
Pediatr Blood Cancer. 2013 Jul;60(7):1073-82
pubmed: 23512831
J Cancer Surviv. 2023 Aug;17(4):1139-1148
pubmed: 35098485
Eur J Cancer Care (Engl). 2016 Nov;25(6):1024-1033
pubmed: 27550385
Pediatr Blood Cancer. 2018 Nov;65(11):e27356
pubmed: 30084222
J Pediatr Psychol. 2010 Apr;35(3):262-74
pubmed: 19578137
J Cancer Surviv. 2010 Sep;4(3):210-7
pubmed: 20383785
J Oncol Pract. 2019 Apr;15(4):e316-e327
pubmed: 30849003
Lancet Oncol. 2022 Apr;23(4):e184-e196
pubmed: 35358467
Leukemia. 2017 Jun;31(6):1450-1453
pubmed: 28218238
J Clin Oncol. 2017 Feb 20;35(6):652-659
pubmed: 28095151
Cancer. 2022 Jul 1;128(13):2405-2419
pubmed: 35435238
Implement Sci Commun. 2021 Sep 16;2(1):106
pubmed: 34530933
Pediatr Blood Cancer. 2016 Jan;63(1):105-11
pubmed: 26398865
JAMA. 2022 Oct 11;328(14):1438-1444
pubmed: 36219403
Oncologist. 2019 May;24(5):710-719
pubmed: 30171066
Pediatr Blood Cancer. 2018 Mar;65(3):
pubmed: 29080381
JAMA. 2022 Oct 18;328(15):1534-1542
pubmed: 36219440
J Natl Compr Canc Netw. 2018 Jan;16(1):66-97
pubmed: 29295883
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):435-46
pubmed: 18268128
BMC Health Serv Res. 2022 Jun 28;22(1):832
pubmed: 35764995